|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.99 USD | -4.31% |
|
-17.02% | +28.45% |
| 03-05 | Evommune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 03-04 | Evommune, Inc. announced that it has received $125.300499 million in funding | CI |
Company Valuation: Evommune, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Capitalization 1 | 539.7 | 792 | - | - |
| Change | - | 46.76% | - | - |
| Enterprise Value (EV) 1 | 539.7 | 517.7 | 481.9 | 483.8 |
| Change | - | -4.07% | -6.92% | 0.39% |
| P/E ratio | -1.53x | -7.89x | -6.81x | -5.76x |
| PBR | - | 3.39x | 2.25x | 3.37x |
| PEG | 0x | 0.1x | -0.4x | -0.3x |
| Capitalization / Revenue | 41.5x | 130x | 772x | 172x |
| EV / Revenue | 41.5x | 84.7x | 470x | 105x |
| EV / EBITDA | -6.77x | -4.63x | -3.44x | -2.89x |
| EV / EBIT | -6.66x | -4.83x | -3.48x | -2.84x |
| EV / FCF | - | -4.9x | -3.93x | -3.21x |
| FCF Yield | - | -20.4% | -25.4% | -31.1% |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -11.22 | -2.786 | -3.23 | -3.82 |
| Distribution rate | - | - | - | - |
| Net sales 1 | 13 | 6.111 | 1.025 | 4.615 |
| EBITDA 1 | -79.68 | -111.9 | -140 | -167.3 |
| EBIT 1 | -81.07 | -107.3 | -138.4 | -170.1 |
| Net income 1 | -68.87 | -106.7 | -136.5 | -174.6 |
| Net Debt 1 | - | -274.3 | -310.2 | -308.3 |
| Reference price 2 | 17.12 | 21.99 | 21.99 | 21.99 |
| Nbr of stocks (in thousands) | 31,524 | 36,018 | - | - |
| Announcement Date | 05/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.89x | 84.72x | -4.63x | - | 792M | |
| 33.07x | 4.92x | 16.5x | 1.02% | 42.78B | |
| 51.27x | 4.42x | 29.75x | -.--% | 31.5B | |
| 54.26x | 11.14x | 30.96x | 0.35% | 29.99B | |
| 19.97x | 2.36x | 10.18x | -.--% | 27.65B | |
| -12.38x | 320.84x | -10.44x | -.--% | 18.8B | |
| 43.12x | 8.22x | 25.82x | -.--% | 13.87B | |
| 26.34x | 4.19x | 19.06x | -.--% | 12.78B | |
| 20.1x | 1.87x | 8.16x | 1.23% | 12.39B | |
| -17.61x | 13.71x | -19.11x | -.--% | 11.76B | |
| Average | 21.02x | 45.64x | 10.63x | 0.29% | 20.23B | |
| Weighted average by Cap. | 29.39x | 35.59x | 15.48x | 0.34% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- EVMN Stock
- Valuation Evommune, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition